KROS - Latest News
Keros Therapeutics, Inc. (KROS), operates in Healthcare / Biotechnology, trades on NASDAQ.
Market capitalization stands near $222.7M. Beta to the broader market is 1.02.
The article list below shows the most recent KROS headlines from major financial news vendors. For options traders, the most actionable items are earnings releases, analyst rating changes, M&A activity, and regulatory filings - each can drive a meaningful repricing of implied volatility and shift dealer hedging flow. Pair the news context with the implied-volatility skew and gamma exposure views to see whether the options market has already priced in the headline.
Recent KROS Headlines
Analyzing Upstream Bio (NASDAQ:UPB) and Keros Therapeutics (NASDAQ:KROS)
defenseworld.net - Oct 5, 2026
Keros Therapeutics (NASDAQ: KROS - Get Free Report) and Upstream Bio (NASDAQ: UPB - Get Free Report) are both small-cap healthcare companies, but whic
KROS Begins Dosing in Phase II Study With Rinvatercept in DMD
zacks.com - Sep 29, 2026
Keros Therapeutics begins dosing in a phase II study of rinvatercept in DMD patients, with initial data expected in the first half of 2027.
Keros Therapeutics to Receive Additional Development Milestone Payment from Partner Takeda
globenewswire.com - Sep 29, 2026
LEXINGTON, Mass. , Sept.
Keros Therapeutics Announces the First Patient Dosing in the Phase 2 Clinical Trial Evaluating Rinvatercept in DMD
globenewswire.com - Sep 28, 2026
LEXINGTON, Mass. , Sept.
Keros Therapeutics Announces $5 Million Share Repurchase Authorization
globenewswire.com - Sep 8, 2026
LEXINGTON, Mass. , Sept.
How News Affects KROS Options Pricing
Headlines and scheduled events drive implied volatility in two distinct ways. Pre-event, IV typically inflates as uncertainty about the outcome rises; this is the implied-volatility expansion that creates the long-vol setup. Post-event, IV typically contracts sharply as uncertainty resolves; this is IV crush, which makes premium-selling structures profitable when they survive the underlying move. The size of the crush depends on how stretched pre-event IV is relative to the realized move. Track KROS's implied vs realized volatility over the news cycle to size pre-event vs post-event positioning. For ticker-level dealer positioning context, the gamma exposure view shows whether dealers are positioned to amplify or dampen post-news moves.
Frequently asked KROS news questions
- What is the latest KROS news headline?
- The most recent KROS headline (Oct 5, 2026) is "Analyzing Upstream Bio (NASDAQ:UPB) and Keros Therapeutics (NASDAQ:KROS)". The five most recent stories with summaries and publication times are listed above, sourced from major financial news vendors.
- How fresh is the KROS news on this page?
- News rows refresh roughly every 30 minutes during the trading day. The five most recent headlines are listed in publication-time order. Press releases from the company itself typically appear within minutes of the wire release; third-party reporting may lag by 30-60 minutes depending on the source.
- What KROS news moves options pricing?
- Three categories move single-name IV most aggressively: scheduled earnings releases (priced into pre-event IV, crushed post-event), unscheduled M&A or strategic announcements (rapid IV expansion, slower decay), and regulatory or legal events (drug-trial readouts, antitrust filings, FDA approvals). Routine news flow (analyst commentary, sector rotation) typically does not move IV meaningfully unless it triggers a cluster of rating changes.
- How can I track unusual KROS options activity related to news?
- Unusual options activity often precedes news by hours to days; the canonical signals are volume substantially above the trailing average concentrated in a small number of strikes, atypical put/call skew, and aggressive execution (at-the-ask sweeps or block prints). Cross-reference the per-ticker gamma-exposure and volume-history pages with the news flow above to triangulate informed vs uninformed flow.